Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CBX7 | O95931 | 1/20 | 0.33 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.33 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.33 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822607 | 0.86 | MAPK1 (0.45) | L3MBTL1L3MBTL3MAPK1MEN1KMT2A | |
| SCHEMBL11008209 | 0.84 | MAPK1 (0.43) | L3MBTL1L3MBTL3MAPK1ALDH1A1 | |
| SCHEMBL11003669 | 0.82 | MAPK1 (0.42) | L3MBTL1L3MBTL3MAPK1MEN1KMT2A | |
| SCHEMBL863778 | 0.80 | MAPK1 (0.43) | L3MBTL1L3MBTL3MAPK1ALDH1A1HRH3 | |
| SCHEMBL863645 | 0.79 | MAPK1 (0.42) | L3MBTL1L3MBTL3MAPK1MEN1KMT2A | |
| SCHEMBL131020 | 0.78 | MAPK1 (0.47) | L3MBTL1L3MBTL3MAPK1ALDH1A1HRH3 | |
| SCHEMBL30475621 | 0.77 | MAPK1 (0.41) | L3MBTL1L3MBTL3MAPK1MEN1KMT2A | |
| SCHEMBL30761740 | 0.77 | MAPK1 (0.41) | L3MBTL1L3MBTL3MAPK1MEN1KMT2A | |
| SCHEMBL7003240 | 0.76 | MAPK1 (0.43) | L3MBTL1L3MBTL3MAPK1ALDH1A1OPRL1 | |
| SCHEMBL5250892 | 0.76 | MAPK1 (0.43) | L3MBTL1L3MBTL3MAPK1ALDH1A1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | GRUENENTHAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | GRUENENTHAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
| WO-2012028331-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE DERIVATIVES | Grünenthal GmbH (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
| US-4886812-A | REGULATING DOPAMINE CONCENTRATION; PARKINSON DISEASE, HYPOTENSIVE AGENT, SCHIZOPHRENIA | DR. KARL THOMAE GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| US-4843086-A | HYPOTENSIVE AGENTS, SCHIZOPHRENIA, PARKINSON'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1989-06-27 | — | — | US | disclosed |
| US-4731374-A | PARKINSON*S DISEASE | DR. KARL THOMAE GMBH (DE) | 1988-03-15 | — | — | US | disclosed |
| EP-0186087-A1 | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs | Dr. Karl Thomae GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
| US-4555537-A | IMIDAZOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | SMN1; SMN2 3310/4885L3MBTL1 4065/4885L3MBTL3 4342/4885 |
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | BDKRB1, BDKRB2, LTB4R | SMN1; SMN2 2489/4885L3MBTL1 4265/4885L3MBTL3 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.